• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Neurogene Inc. - Common Stock (NQ:NGNE)

    17.68 -0.94 (-5.05%)
    Streaming Delayed Price Updated: 3:38 PM EST, Feb 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 141,566
    Open 18.38
    Bid (Size) 17.32 (100)
    Ask (Size) 17.68 (200)
    Prev. Close 18.62
    Today's Range 17.43 - 18.80
    52wk Range 6.875 - 37.27
    Shares Outstanding 42,425,071
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Neurogene to Participate in Upcoming Investor Conferences
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Neurogene Inc.
    Via Business Wire

    Performance

    YTD
    -12.3%
    -12.3%
    1 Month
    +0.9%
    +0.9%
    3 Month
    -13.3%
    -13.3%
    6 Month
    -10.5%
    -10.5%
    1 Year
    +4.2%
    +4.2%

    More News

    Read More
    News headline image
    Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Neurogene Inc.
    Via Business Wire
    News headline image
    FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
    From Neurogene Inc.
    Via Business Wire
    News headline image
    4 Biotech Stocks Seeing Explosive Momentum Gains ↗
    Via Benzinga
    Topics ETFs Stocks
    News headline image
    Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Neurogene Inc.
    Via Business Wire
    News headline image
    FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
    Via Benzinga
    News headline image
    Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗
    Via Benzinga
    News headline image
    Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Neurogene Inc.
    Via Business Wire
    News headline image
    What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Neurogene Inc.
    Via Business Wire
    News headline image
    Which stocks are moving on Tuesday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Neurogene Inc. - Common Stock publicly traded?
    Yes, Neurogene Inc. - Common Stock is publicly traded.
    What exchange does Neurogene Inc. - Common Stock trade on?
    Neurogene Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Neurogene Inc. - Common Stock?
    The ticker symbol for Neurogene Inc. - Common Stock is NGNE on the Nasdaq Stock Market
    What is the current price of Neurogene Inc. - Common Stock?
    The current price of Neurogene Inc. - Common Stock is 17.68
    When was Neurogene Inc. - Common Stock last traded?
    The last trade of Neurogene Inc. - Common Stock was at 02/20/26 03:38 PM ET
    What is the market capitalization of Neurogene Inc. - Common Stock?
    The market capitalization of Neurogene Inc. - Common Stock is 750.08M
    How many shares of Neurogene Inc. - Common Stock are outstanding?
    Neurogene Inc. - Common Stock has 750M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.